Journals / Arşiv Kaynak Tarama Dergisi / 2014 / Cilt: 23 - Sayı: 1

Management of Viral Infections in Allogenic Hematopoietic Stem Cell Transplanted Children

Allojenik Hematopoetik Kök Hücre Transplant Alıcılarında Viral İnfeksiyonların Yönetimi

Pages
118–136
Publication Date
2014-10-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Viral infections associated with high morbidity and mortality in HSCT patients can be prevented by early diagnosis through the molecular diagnostic techniques and timely initiation of appropriate treatment options.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Viral infections such as herpes viruses (CMV, EBV, HHV-6, HSV-1 and 2, VZV), adenovirus, and polyomavirus (BK virus) may lead to considerable morbidity and mortality in allogenic hematopoietic stem cell transplanted children (HSCT), mainly due to iatrogenic T cell dysfunction.
📊
Key Findings & Data:To manage these infections, different strategies like matching of host and donor, viral surveillance, antiviral prophylaxis and preemptive antiviral treatment have been tried and combined, since these infections have become more recognised and can be monitored by quantitative real-time polymerase chain reaction.
💡
Conclusion & Impact:Viral infections associated with high morbidity and mortality in HSCT patients can be prevented by early diagnosis through the molecular diagnostic techniques and timely initiation of appropriate treatment options.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:viral enfeksiyonlar · hematopoetik kök hücre transplantasyonu · çocuklar

Abstract

Viral infections such as herpes viruses (CMV, EBV, HHV-6, HSV-1 and 2, VZV), adenovirus, and polyomavirus (BK virus) may lead to considerable morbidity and mortality in allogenic hematopoietic stem cell transplanted children (HSCT), mainly due to iatrogenic T cell dysfunction. To manage these infections, different strategies like matching of host and donor, viral surveillance, antiviral prophylaxis and preemptive antiviral treatment have been tried and combined, since these infections have become more recognised and can be monitored by quantitative real-time polymerase chain reaction. Viral infections associated with high morbidity and mortality in HSCT patients can be prevented by early diagnosis through the molecular diagnostic techniques and timely initiation of appropriate treatment options.

Özet

Herpes viruslar (CMV, EBV, HHV-6, HSV-1 ve 2, VZV), adenovirus ve polyomavirus (BK virus) gibi viral infeksiyonlar allojenik hematopoetik kök hücre (HSCT) nakledilen çocuklarda başlıca iatrojenik T hücre fonksiyon bozukluğu sebebi ile önemli morbidite ve mortaliteye yol açabilir. Bu infeksiyonların kantitatif gerçek zamanlı polimeraz zincir reksiyonu ile tanınabilir ve monitorize edilebilir hale gelmesinden bu yana, infeksiyonların yönetimi için alıcı ve donör eşleştirmesi, viral surveyans, antiviral profilaksi ve preemptif antiviral tedavi denenmiş ve kombine edilmiştir. HSCT hastalarında yüksek morbidite ve mortalite ile seyreden viral infeksiyonlar moleküler tanı teknikleri ile erken tanı ve uygun tedavi seçeneklerinin zamanında başlanması ile önlenebilmektedir.

🔖

Cite This Article

GÜMÜŞ, H. H., YARKIN, F. (2014). Management of Viral Infections in Allogenic Hematopoietic Stem Cell Transplanted Children. Arşiv Kaynak Tarama Dergisi, Cilt: 23 - Sayı: 1, 118–136. https://ajindex.com/articles/466137

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Breuer S, Rauch M, Matthes-Martin S, Lion T. Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients. Mol Diagn Ther. 2012; 16:63-77.
  2. Brooks GF, Carrol KC, Butel JS, Morse SA, Mietzner TA. Jawetz, Melnick & Adelberg’s Medical Microbiology 26 th Ed. Colombus, OH, McGraw-Hill, 2013.
  3. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011; 25:151-69.